| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PRDX6 |
| Uniprot No | P30041 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-224aa |
| 氨基酸序列 | PGGLLLGDV APNFEANTTV GRIRFHDFLG DSWGILFSHP RDFTPVCTTE LGRAAKLAPE FAKRNVKLIA LSIDSVEDHL AWSKDINAYN CEEPTEKLPF PIIDDRNREL AILLGMLDPA EKDEKGMPVT ARVVFVFGPD KKLKLSILYP ATTGRNFDEI LRVVISLQLT AEKRVATPVD WKDGDSVMVL PTIPEEEAKK LFPKGVFTKE LPSGKKYLRY TPQP |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PRDX6重组蛋白的3篇代表性文献及其简要摘要：
1. **文献名称**：Peroxiredoxin 6: A Bifunctional Enzyme with Glutathione Peroxidase and Phospholipase A₂ Activities
**作者**：Chen JW, et al.
**摘要**：该研究首次揭示了PRDX6蛋白具有双重酶活性，既能作为谷胱甘肽过氧化物酶清除过氧化氢，又能通过钙非依赖性磷脂酶A₂(iPLA₂)活性参与细胞膜修复。重组PRDX6蛋白的体外实验验证了其双重功能机制。
2. **文献名称**：Recombinant Human Peroxiredoxin 6 Exhibits Protective Effects in a Murine Model of Acute Lung Injury
**作者**：Wang Y, et al.
**摘要**：通过大肠杆菌表达系统成功制备重组人PRDX6蛋白，并在脂多糖诱导的小鼠急性肺损伤模型中验证其抗氧化和抗炎作用。结果显示，重组PRDX6显著降低肺部氧化应激标志物并改善病理损伤。
3. **文献名称**：Structural Basis for the Catalytic Mechanism of Human Peroxiredoxin 6
**作者**：Ralat LA, et al.
**摘要**：该研究通过X射线晶体学解析了重组人PRDX6的三维结构，阐明了其依赖谷胱甘肽而非硫氧还蛋白的独特催化机制，并揭示了iPLA₂活性中心的关键氨基酸残基，为靶向药物设计提供结构基础。
如需更多文献，可进一步补充。
Peroxiredoxin 6 (PRDX6) is a multifunctional antioxidant enzyme belonging to the peroxiredoxin family, which plays a critical role in cellular defense against oxidative stress. Unlike other peroxiredoxins, PRDX6 uniquely combines glutathione peroxidase (GPx) and calcium-independent phospholipase A2 (iPLA2) activities, enabling it to neutralize reactive oxygen species (ROS) and regulate lipid metabolism. This 25-kDa protein is expressed ubiquitously in mammalian tissues, with high concentrations in the lungs, liver, and brain, where oxidative damage is a key factor in pathologies like neurodegenerative diseases, cancer, and acute lung injury.
Recombinant PRDX6 proteins are engineered using expression systems such as *E. coli* or mammalian cell lines (e.g., HEK293) to study its structure-function relationships or therapeutic potential. The recombinant form retains dual enzymatic activities, allowing researchers to explore its redox regulation mechanisms and membrane repair functions. Studies highlight its ability to mitigate oxidative damage by reducing peroxides through its GPx domain, while the iPLA2 activity aids in phospholipid turnover and cell signaling. This dual functionality makes PRDX6 a unique target for developing therapies against diseases linked to oxidative stress and inflammation.
Recent research focuses on PRDX6's role in modulating cellular apoptosis, inflammation, and tissue repair. Its recombinant variants are investigated for applications in drug delivery, gene therapy, and as biomarkers for oxidative stress-related conditions. Challenges remain in optimizing stability, tissue-specific targeting, and minimizing off-target effects. Nonetheless, PRDX6 recombinant proteins continue to offer promising avenues for understanding redox biology and advancing precision medicine.
×
